BIOMATERIALS BILL WITH BREAST IMPLANT EXCLUSION ACCEPTED BY HIMA BOARD
This article was originally published in The Gray Sheet
Executive SummaryBiomaterials liability legislation that excludes breast implants has the best chance of passage in the 105th Congress, the Health Industry Manufacturers Association has concluded. HIMA's board, meeting the week of Dec. 9, decided that work on biomaterials liability reform should begin in January where it ended in September: with a silicone breast implant "carve-out" that would exclude manufacturers of those products from liability protection under the bill.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.